Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RDY 
Dr. Reddy’s Laboratories Ltd ADR (RDY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RDY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -10.29% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.12B USD | Price to earnings Ratio 17.59 | 1Y Target Price 15.1 |
Price to earnings Ratio 17.59 | 1Y Target Price 15.1 | ||
Volume (30-day avg) 1879923 | Beta 0.35 | 52 Weeks Range 12.50 - 16.89 | Updated Date 04/1/2025 |
52 Weeks Range 12.50 - 16.89 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.72% | Basic EPS (TTM) 0.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 17.24% | Operating Margin (TTM) 22.38% |
Management Effectiveness
Return on Assets (TTM) 10.32% | Return on Equity (TTM) 18.47% |
Valuation
Trailing PE 17.59 | Forward PE 15.15 | Enterprise Value 11047424060 | Price to Sales(TTM) 0.04 |
Enterprise Value 11047424060 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 3.04 | Enterprise Value to EBITDA 10.3 | Shares Outstanding 833152000 | Shares Floating 595956431 |
Shares Outstanding 833152000 | Shares Floating 595956431 | ||
Percent Insiders - | Percent Institutions 15.04 |
Analyst Ratings
Rating 3.2 | Target Price 15.14 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Dr. Reddy’s Laboratories Ltd ADR
Company Overview
History and Background
Dr. Reddyu2019s Laboratories Ltd was founded in 1984 by Kallam Anji Reddy. It started as a supplier to Indian drug manufacturers and later expanded into finished dosages and generic pharmaceuticals. Over time, it has evolved into a global pharmaceutical company with a focus on innovation and research.
Core Business Areas
- Pharmaceutical Services & Active Pharmaceutical Ingredients (PSAI): This segment focuses on manufacturing and supplying active pharmaceutical ingredients to generic and branded formulation companies worldwide.
- Global Generics: This segment involves the development, manufacturing, and marketing of generic pharmaceutical products across various therapeutic areas.
- Proprietary Products: This segment focuses on the development and commercialization of differentiated formulations and novel drugs, including specialty products and biosimilars.
Leadership and Structure
The company is led by a board of directors and a management team headed by the CEO. The organizational structure includes various business units and functional departments, such as research and development, manufacturing, marketing, and finance.
Top Products and Market Share
Key Offerings
- Generic Pharmaceuticals: Dr. Reddy's manufactures and sells a wide range of generic drugs across various therapeutic areas, including cardiovascular, anti-infectives, pain management, and oncology. Market share varies by product and region. Key competitors include Teva, Mylan, and Sun Pharma. Revenue figures are not typically broken down by individual generic product.
- Specialty Pharmaceuticals: Dr. Reddy's develops and markets specialty products addressing specific patient needs, often involving differentiated formulations or delivery mechanisms. Details about product specific marketshare not found in public domain. Revenue figures are not typically broken down by individual specialty product. Competition includes other players in specialty pharma such as AbbVie and Amgen depending on therapeutic area.
- Active Pharmaceutical Ingredients (APIs): Dr. Reddy's is a significant supplier of APIs to other pharmaceutical companies. The exact market share can fluctuate. Competitors include various API manufacturers in India and China. Revenue figures are not typically broken down by specific API.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, stringent regulations, and a constant need for innovation. Growth is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology.
Positioning
Dr. Reddy's is positioned as a global pharmaceutical company with a focus on generics, specialty products, and APIs. Its competitive advantages include its vertically integrated manufacturing capabilities, strong research and development capabilities, and established presence in key markets.
Total Addressable Market (TAM)
The global pharmaceuticals market is estimated to be over $1 trillion. Dr. Reddyu2019s is positioned to capture a share of this market through its generics, APIs and specialty products.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Vertically integrated manufacturing
- Global presence
- Diversified product portfolio
- Experienced management team
Weaknesses
- Dependence on generic drug sales
- Exposure to pricing pressure
- Regulatory risks
- Reliance on specific markets
- Competition from larger players
Opportunities
- Expanding into new markets
- Developing innovative products
- Acquiring complementary businesses
- Partnering with other companies
- Capitalizing on biosimilar opportunities
Threats
- Increasing competition
- Pricing pressure
- Regulatory changes
- Intellectual property challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- SUNPHARMA.NS
Competitive Landscape
Dr. Reddy's faces competition from both generic and branded pharmaceutical companies. It aims to differentiate itself through its R&D capabilities, vertically integrated manufacturing, and focus on select therapeutic areas. Its generic competition faces pressure from pricing and biosimilars have high development cost to enter a market.
Major Acquisitions
Imperial Chemical Industries' API business
- Year: 2005
- Acquisition Price (USD millions): 26.5
- Strategic Rationale: Expanded Dr. Reddy's API manufacturing capabilities and global reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require accessing and processing historical financial data.
Future Projections: Future growth projections require accessing and analyzing analyst estimates.
Recent Initiatives: Recent strategic initiatives are continuously changing; this requires dynamic information gathering from press releases and company reports.
Summary
Dr. Reddy's is a global pharmaceutical company with strengths in R&D and manufacturing. While it benefits from a diversified product portfolio, its reliance on generics exposes it to pricing pressure. Opportunities lie in expanding into new markets and developing innovative products. The company needs to watch out for increasing competition and regulatory changes, while having a strong standing in the current market.
Similar Companies
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Company Website
- Financial Reports
- Industry Analysis Reports
- Market Data Providers
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market conditions and company performance can change rapidly. Data are estimates based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dr. Reddy’s Laboratories Ltd ADR
Exchange NYSE | Headquaters - | ||
IPO Launch date 2001-04-11 | CEO & Member of the Management Council Mr. Erez Israeli M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 27048 | Website https://www.drreddys.com |
Full time employees 27048 | Website https://www.drreddys.com | ||
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.